Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by PepGen Inc.

PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen to Participate in the SVB Securities Global Biopharma Conference
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies
From PepGen Inc.
Via GlobeNewswire
Tickers PEPG
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.